A special thank you to The ASCO Post Editorial Board, editorial team, contributors, and readers whose dedication and support have helped make The ASCO Post one of the most-read sources of oncology news worldwide. Together, we continue to advance cancer care through education.

ℹ️ Researchers found patients with missing case information in the SEER database had substantially worse 3-year survival outcomes across several cancer types ➡️ Concerns for cancer research & AI models 🔹 Drs. Marmor & White | Journal of the American College of Surgeons (JACS) https://ow.ly/MR0Y50Z2P4J

🔬 In new data, individuals with POT1 variants had unusually long telomeres and an 8-fold higher risk of lymphoma, with 45% developing a #lymphoidcancer by 80. ☑️ Insights into telomere biology and cancer susceptibility. 🔸 The Sidney Kimmel Comprehensive Cancer Center 🔗 https://ow.ly/FIqC50Z14QR#lymphoidcancer

⏰ Could timing influence #immunotherapy outcomes? A new meta-analysis found earlier time-of-day immune checkpoint inhibitor administration was associated with improved OS and PFS across several advanced cancers. 🔹 Inoue et al | JAMA Network Open Read more: https://ow.ly/82y250Z14ON#immunotherapy

🖥️ ASCO AI: The U.S. Food and Drug Administration upgraded #AI platform, Elsa 4.0, signals where health care is headed: ✅ Reduced administrative burden ✅ Faster protocol reviews ✅ More scalable regulatory workflows A notable step for AI in oncology & drug development. https://ow.ly/Up4O50Z0lcC#AI

🩸 Researchers identified blood-based biomarkers that may help distinguish inflammatory #breastcancer from non–inflammatory breast cancer, possibly with liquid biopsies. #BCSM ➡️ Potential implications for diagnosis, monitoring & therapeutic development. https://ow.ly/QBHT50Z0l9Q#breastcancer

🧬 Perioperative #immunotherapy gains momentum in upper #GIcancers Phase II data from NEOSUMMIT-01 showed toripalimab + perioperative chemotherapy improved 3-year OS rate in locally advanced gastric/GEJ cancer: 81.3% vs 72.2% 🔹Nie et al 🔗 https://ow.ly/4Gvf50Z0l8Q#immunotherapy

In a phase 2️⃣ trial, early B-cell depletion with obinutuzumab significantly reduced corticosteroid-requiring chronic GVHD after allogeneic transplant: ➡️ 13.3% vs 35.2% at 1 year 👨‍⚕️ Corey Cutler, MD of Dana-Farber Read more 👉 https://ow.ly/6pZl50YZ2qX

🥇 The @ASCO Certified Program has certified its first virtual cancer clinic. Color’s AI-enabled Virtual Cancer Clinic supports patients across screening, diagnosis, treatment, and survivorship with nationwide oncologist-led care. 💻 Virtual #oncologycare continues to evolve. https://ow.ly/mRR050YZ2oc

🖥️ #ASCOAI: As #AI-generated deepfakes become more sophisticated, the @AmerMedicalAssn is calling for stronger protections around physician identity, consent, and transparency to help prevent medical misinformation. Learn more: https://ow.ly/YEoO50YYTtO#ASCOAI

After 9 lines of therapy, 4 clinical trials, radiation, major surgery, and metastatic progression, Bill Thach continues living with advanced neuroendocrine carcinoma of the rectum while navigating each new treatment option. Read this powerful perspective: https://ow.ly/xPVy50YYTrV

🆕 @ASCO guidance highlights how molecular testing is reshaping #thyroidcancer management. The guideline addresses sequencing, toxicity, and integration of targeted therapies across differentiated, anaplastic, and medullary thyroid cancers. Learn more ➡️ https://ow.ly/fKzp50YYTsG#thyroidcancer

🩸 Leukemia care has transformed in 50 years From TKIs in CML to bispecifics, CAR-T, and MRD-guided therapy in ALL/AML, outcomes once thought impossible are becoming reality. Read this insightful perspective from Hagop Kantarjian, M.D. of MD Anderson: https://ow.ly/qczy50YXyIr

🫀In a cohort of patients with #melanoma on BRAF/MEK inhibitors: • 46% developed hypertension • 46% developed treatment-related cardiac dysfunction ☑️ Most cases mild; moderate/severe events appeared as early as 4 weeks 🔹 Glen et al https://ow.ly/1JpN50YXyHu#melanoma

🫂 A powerful reminder in oncology care: communication is care In this thoughtful commentary from Dr. Muhammad Rafiqul Islam, he details how trust, listening, empathy, and patient perception influence the experience and effectiveness of oncology care. 🔗 https://ow.ly/3Klb50YXyEK

🖥️ #ASCOAI: Agentic AI may help drive new cancer developments, guide treatment decisions. The SPARK framework autonomously generated biomarker hypotheses, validated prognostic markers, & uncovered new insights into tumor evolution in 5 cancer types. Learn more ➡️ https://ow.ly/m4Tj50YXyFL#ASCOAI

Don’t miss out on your chance to join leaders in AI-enabled cancer care for a discussion on how AI is advancing precision oncology, improving patient care, and helping clinicians make more informed treatment decisions. 📅 May 20 | 8 PM ET https://ascoai.broadcastmed.io/live/1/page/1

🔬 Belzutifan + lenvatinib may reshape post–IO care in advanced RCC. In phase III LITESPARK-011, the combo improved PFS (14.8 vs 10.7 months), ORR vs cabozantinib. ➡️ Trend toward OS benefit. https://ow.ly/xREY50YUy4Y

#ASCOAI: OpenAI has launched ChatGPT for Clinicians, a new #AI assistant for clinical workflows 👉 Built with physician input, early data shows strong performance across specialties, including hematology/oncology. https://ascoai.org/articles/2026/04/openai-launches-new-clinical-chatbot/#ASCOAI

🚹 Prostate Cancer overdiagnosis rises sharply with age. New data show risk increases from 16% at age 50 to 58% by age 80 following PSA screening. ➡️ Authors call for more targeted, age-informed PSA testing. 👨‍⚕️ Adam Brentnall, PhD | #PCSM 🔗 https://ow.ly/Kfp150YUy3u#PCSM

👤 AI meets oncology in a new way: Tracking changes in biological age using facial images (“FaceAge”) offers real-time insights into patient health and prognosis. ☑️ Accessible, scalable, and noninvasive. 🔹 Raymond Mak, MD | Nature Communications 🔗 https://ow.ly/C6Ea50YUy2Y

🔬 Improving clinical trial diversity may require new approaches New findings suggest political ideology may influence skepticism toward trials, with implications for enrollment, diversity, and equity in cancer research. 🔸 Chido-Amajuoyi et al | JAMA Network Open https://ow.ly/Xwk050YUuYm

🧬 Amivantamab shows promise in chemorefractory CRC. In the OrigAMI-1 trial, the EGFR-MET bispecific antibody demonstrated durable responses across tumor sidedness and prior anti-EGFR exposure. 🔹 Paul E. Oberstein, MD of NYU Langone 🔗 https://ow.ly/lCC850YUuXj

A large multisite study explored the true benefits of AI ambient scribe adoption, demonstrating a limited magnitude of clinical benefit. ⏱️ Small time savings 📈 Slight volume increase Explore the findings: https://ow.ly/xu2K50YS3Tg

🩸Post-transplant monitoring may be evolving. An AI-powered NGS blood test identified patients at high risk for relapse months after HCT, potentially enabling earlier intervention in AML/MDS. 🗣️ Presented by Ran Reshef, MD, MSc Learn more: https://ow.ly/PAB550YUuX2

🚨 New American College of Physicians (ACP) #breastcancer screening guidelines recommend: • Biennial screening (ages 50–74) • Individualized decisions (ages 40–49) ⚠️ Experts warn this could lead to more advanced cancers and worse outcomes. Read the full article ➡️ https://ow.ly/Ek6u50YS3RN#breastcancer

🚺 Treatment decisions in advanced #endometrialcancer aren’t straightforward. In this roundtable, experts dive into: ☑️ Applying trial data + guidelines ☑️ Treating without measurable disease ☑️ Navigating post-IO recurrence 🎥 Watch here: https://ow.ly/qpRT50YS3QC#endometrialcancer

🌟 Unprecedented benefit seen in patients with pancreatic cancer treated with daraxonrasib (RAS inhibitor) leading to potential paradigm shifts 🥼 Presentations from Brian Wolpin, MD, MPH & Eileen O’Reilly, MD 🔗 https://ow.ly/EyIm50YS3P8

🖥️ ASCO AI: Precision Oncology starts with knowing where cancer begins. A machine learning model using a reduced set of methylation markers achieved strong cross-cohort performance, unlocking new potential for personalized treatment. Read the article ➡️ https://ow.ly/PP9Z50YP4hP

💉 Intralesional nivolumab may change how we manage precancerous oral lesions In phase 1️⃣ data: • 85% response rate • ~60% ⬇️ in lesion size • Some patients avoided surgery 🗣️ Presented by Moran Amit, MD, PhD at AACR26 Read more: https://ow.ly/tuV250YP4eq

🔥 As wildfires intensify, so do long-term health concerns. New findings suggest carcinogenic effects beyond the lungs, with increased risk across multiple cancer types. 🗣️ Presented by Qizhen Wu, PhD, and Shuguang Leng, MBBS, PhD at AACR26 https://ow.ly/U6j950YP496

🆕 The April issue of The ASCO Post is LIVE, featuring highlights from #MBCC26, #GI26, #GU26; perspectives on prostate cancer screening; an interview with Eli Van Allen on #AI in cancer research; and MORE! Read the full issue 👉 https://ascopost.com/issues/april-25-2026/#MBCC26

Is AI quietly reshaping clinical expertise? A new review suggests routine #AI use may weaken clinical skills through automation bias, reduced independent judgment, fewer training opportunities. 🔹 Pierre E. Heudel, MD | ESMO - European Society for Medical Oncology 🔗 https://ow.ly/6yls50YNtZO#AI

The FDA rejected a proposal to fast-track radiology #AI devices without 510(k) premarket review, emphasizing patient safety and the limits of postmarket monitoring. Learn more by reading the full article 👉 https://ow.ly/AFKi50YNu8R

Updated NCCN guidance recommends starting breast cancer screening at age 35 for women identified as high-risk through AI models or other validated risk assessment tools. ➡️ This signals a broader move toward data-driven, individualized screening pathways. https://ow.ly/WFjY50YLecm

Managing advanced RCC after adjuvant immunotherapy In this roundtable discussion, experts explore treatment strategies for patients with disease progression following adjuvant pembrolizumab. 🎥 : https://ow.ly/o2FW50YLe9Q

📊 New global data on childhood cancer survival assess progress toward World Health Organization targets For pediatric oncology, these findings reinforce the need for continued investment in equitable cancer care worldwide. ➡️ 60% target may not be high enough https://ow.ly/nI9Z50YLe2e

#ASCOAI: A new perspective from Eddy Saad, MD, MSc of Dana-Farber Cancer Institute, explores how synthetic real-world data can help accelerate clinical trials, improve efficiency, and support better-informed decisions, all while safeguarding patient privacy. https://ow.ly/zkzg50YJR4E

📢 Advancing treatment options in hepatobiliary cancers A study highlights that ablative radiotherapy with chemotherapy may improve outcomes in patients with large intrahepatic cholangiocarcinoma. Led by Ethan Ludmir, MD and Eugene Koay, MD, PhD Read more: https://ow.ly/BlPt50YJQXq

🫁 Lung cancer isn’t limited to smokers. New research suggests that a one-time low-dose CT screening may reduce lung cancer mortality among never-smokers in Asia. Findings presented at hashtag#ELCC26; with commentary from Marina Chiara Garassino, MD https://ow.ly/QASi50YJQUr

👁️ Phase II CHOPIN trial: Adding nivolumab + ipilimumab to percutaneous hepatic perfusion significantly improved progression-free survival in patients with metastatic uveal melanoma. 🔸 van den Hoek et al 🔗 https://ow.ly/IroH50YuWoW

📢 FDA update: New draft guidance on biosimilar development may streamline testing requirements and reduce development costs—potentially helping expand access to lower-cost biologic medicines. 🔗 https://ascopost.com/news/march-2026/fda-releases-updated-guidance-on-biosimilar-development/

🎉 Peter WT Pisters, MD, President of UT MD Anderson Cancer Center was recognized at #SSO2026 with the Charles M. Balch, MD, Distinguished Service Award for advancing surgical oncology through leadership, research, and training. Read the full article ➡️ https://ow.ly/PHle50Yssax#SSO2026

🖥️ ASCO AI - This week in review: ✔️ FDA-approved AI tool for intraoperative breast cancer margin assessment ✔️ Research on how AI pathology models identify biomarkers ✔️ Deep learning classifier for pediatric brain tumors via liquid biopsy 🎥 Watch now: https://ow.ly/mLaB50YqhE8

🚺 TRAIN-3 evaluates the use of MRI to guide the duration of neoadjuvant chemo in HER2+ breast cancer. ▪️ 3-yr EFS favorable ▪️ Minimizes toxicity ▪️ Preserves QOL ✍️ Gabe Sonke, MD of The Netherlands Cancer Institute 🔗 https://ow.ly/itxX50YoBO4

🌟Introducing the advisory board for ASCO AI in Oncology: 🔹Editor-in-Chief Ravi B. Parikh, MD, MPP, FACP 🔹Kenneth L. Kehl, MD, MPH 🔹Danielle S. Bitterman, MD 🔹Travis Zack, MD, PhD 🔹Jame Abraham, MD, FACP https://ascoai.org/editorial-advisory-board/

New computational biomarker (TmS) may better predict chemotherapy response in pts with triple-negative breast cancer than current methods; identified high-TmS (favorable) vs low-TmS (poor prognosis) groups. 🔸 Wenyi Wang, PhD | Cell Reports Medicine Learn more ➡️ https://ow.ly/JXhx50YmrR0

💻 ASCO AI: Can federated learning accelerate precision oncology? The Cancer AI Alliance is training #AI models across 4 NCI cancer centers—without sacrificing patient privacy. 📝️ Interview with Eliezer Van Allen, MD 🔗 https://ow.ly/N31j50YmEQW

🆕 The February issue of The ASCO Post is LIVE! This issue features: highlights from GI 2026, ASH 2025, ESMOAI 2025; an interview with Kimmie Ng, MD on early-onset GI cancers; perspectives on AML treatment shifts; and MORE! Read the full issue 👉 https://ascopost.com/issues/february-25-2026/

🧠 New AI deep learning approach (M-PACT) may enable the identification and classification of pediatric brain tumors from a liquid biopsy using cerebrospinal fluid. ✍️ Katie Han & Kyle Smith, PhD of St. Jude Children's Research Hospital | Nature Cancer 🔗 https://ow.ly/Lr5H50Yl51r